Woodbranch personal page - To The Moon

Woodbranch

Woodbranch

No personal profile

5Follow

5Followers

0Topic

0Badge

08-19

$NoonTalk Media(SEJ.SI)$ Hitting 0 soon

07-29

If getting suppliers locally is going to cut down on all the logistic costs, but still cost us more to buy them. Then no thanks.

Singapore Is Running Out of Time to Meet its Food Supply Goal

07-18

Share your opinion about this news…

BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch

02-07

Anyone has the full article

Sorry, the original content has been removed

2022-03-08

$Grab Holdings(GRAB)$if i had bought this during ipo, i might be working for them slogging for that extra income to fill the gaps

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3583414482292207","uuid":"3583414482292207","gmtCreate":1620322003768,"gmtModify":1635519388186,"name":"Woodbranch","pinyin":"woodbranch","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","hatId":"ca_profile_frame_5b7Fd6","hatName":"LV5 头像框","vip":1,"status":2,"fanSize":5,"headSize":5,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":5,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.15","exceedPercentage":"60.10%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.02.01","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":1,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":340162317475968,"gmtCreate":1724051661746,"gmtModify":1724051665710,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SEJ.SI\">$NoonTalk Media(SEJ.SI)$</a> Hitting 0 soon","listText":"<a href=\"https://ttm.financial/S/SEJ.SI\">$NoonTalk Media(SEJ.SI)$</a> Hitting 0 soon","text":"$NoonTalk Media(SEJ.SI)$ Hitting 0 soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/340162317475968","isVote":1,"tweetType":1,"viewCount":119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":332647088873720,"gmtCreate":1722220519167,"gmtModify":1722220523230,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"If getting suppliers locally is going to cut down on all the logistic costs, but still cost us more to buy them. Then no thanks.","listText":"If getting suppliers locally is going to cut down on all the logistic costs, but still cost us more to buy them. Then no thanks.","text":"If getting suppliers locally is going to cut down on all the logistic costs, but still cost us more to buy them. Then no thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/332647088873720","repostId":"1162539099","repostType":2,"repost":{"id":"1162539099","pubTimestamp":1722218363,"share":"https://ttm.financial/m/news/1162539099?lang=&edition=fundamental","pubTime":"2024-07-29 09:59","market":"sg","language":"en","title":"Singapore Is Running Out of Time to Meet its Food Supply Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=1162539099","media":"Bloomberg","summary":"Singaporeans love fresh food. So you’d think that produce from local farms would be in high demand. Yet local farmers say we’re not eating our home-grown produce. Family and friends often exclaim over","content":"<html><head></head><body><p>Singaporeans love fresh food. So you’d think that produce from local farms would be in high demand. Yet local farmers say we’re not eating our home-grown produce. Family and friends often exclaim over organic Australian crops and fruit from New Zealand, but I’ve never heard anyone rave about Singaporean vegetables.</p><p style=\"text-align: start;\">While researching a story on the troubles facing local producers, many of the farmers I spoke to said they are running out of options as private investment dries up and government grants set a high bar for technology.</p><p style=\"text-align: start;\">Traditional fish farmer Kai Wong told me he slashed prices by 20% to work with local restaurants for an upcoming event, but still received complaints that Malaysian produce was cheaper. Ironically, the event will be for National Day. His farm already supplies its own restaurant and fish soup stall to rely less on other local businesses. “It’s not foolproof, but I’m cornered. I don’t have any other ideas,” he said.</p><p>Even before getting their produce to the domestic market, farmers must overcome operational challenges and long waits for a myriad of licenses.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/b97a3bde81fca2ccf6cb25c12f7efa43\" alt=\"Operations at LivFresh Pte Farm\" title=\"Operations at LivFresh Pte Farm\" tg-width=\"2000\" tg-height=\"1334\"/><span>Operations at LivFresh Pte Farm</span></p><p style=\"text-align: start;\">Their struggles reflect Singapore’s dilemma as an island that is a global trading port but has very little land. Maintaining a free-trade environment means local producers must compete equally with regional and global suppliers. Yet, the Singapore Food Agency has a stated goal of increasing local output to 30% of the nation’s nutritional needs by 2030.</p><p style=\"text-align: start;\">“The ‘30 by 30’ vision is a stretched ambition but an important one to ensure that local produce can serve as a buffer during supply disruptions,” the agency said.</p><p style=\"text-align: start;\">As some traditional farms close, Singapore has been experimenting with new systems for offshore fish farming, as well as rooftop and vertical farms, lab-grown meat, and even insects. Yet many of the ventures are still unprofitable or have high costs.</p><p>Local production of vegetables and seafood in 2023 decreased by 15% and 8% respectively from 2022, according to the SFA. Both sectors supply a smaller percentage of the nation’s consumption since the agency set its “30 by 30” goal in 2019.</p><p style=\"text-align: start;\">With time running out, the industry may need a new approach — or a new target.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Singapore Is Running Out of Time to Meet its Food Supply Goal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSingapore Is Running Out of Time to Meet its Food Supply Goal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-29 09:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.bloomberg.com/news/newsletters/2024-07-27/singapore-food-goal-in-jeopardy-as-residents-shun-local-produce><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Singaporeans love fresh food. So you’d think that produce from local farms would be in high demand. Yet local farmers say we’re not eating our home-grown produce. Family and friends often exclaim over...</p>\n\n<a href=\"https://www.bloomberg.com/news/newsletters/2024-07-27/singapore-food-goal-in-jeopardy-as-residents-shun-local-produce\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://www.bloomberg.com/news/newsletters/2024-07-27/singapore-food-goal-in-jeopardy-as-residents-shun-local-produce","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162539099","content_text":"Singaporeans love fresh food. So you’d think that produce from local farms would be in high demand. Yet local farmers say we’re not eating our home-grown produce. Family and friends often exclaim over organic Australian crops and fruit from New Zealand, but I’ve never heard anyone rave about Singaporean vegetables.While researching a story on the troubles facing local producers, many of the farmers I spoke to said they are running out of options as private investment dries up and government grants set a high bar for technology.Traditional fish farmer Kai Wong told me he slashed prices by 20% to work with local restaurants for an upcoming event, but still received complaints that Malaysian produce was cheaper. Ironically, the event will be for National Day. His farm already supplies its own restaurant and fish soup stall to rely less on other local businesses. “It’s not foolproof, but I’m cornered. I don’t have any other ideas,” he said.Even before getting their produce to the domestic market, farmers must overcome operational challenges and long waits for a myriad of licenses.Operations at LivFresh Pte FarmTheir struggles reflect Singapore’s dilemma as an island that is a global trading port but has very little land. Maintaining a free-trade environment means local producers must compete equally with regional and global suppliers. Yet, the Singapore Food Agency has a stated goal of increasing local output to 30% of the nation’s nutritional needs by 2030.“The ‘30 by 30’ vision is a stretched ambition but an important one to ensure that local produce can serve as a buffer during supply disruptions,” the agency said.As some traditional farms close, Singapore has been experimenting with new systems for offshore fish farming, as well as rooftop and vertical farms, lab-grown meat, and even insects. Yet many of the ventures are still unprofitable or have high costs.Local production of vegetables and seafood in 2023 decreased by 15% and 8% respectively from 2022, according to the SFA. Both sectors supply a smaller percentage of the nation’s consumption since the agency set its “30 by 30” goal in 2019.With time running out, the industry may need a new approach — or a new target.","news_type":1},"isVote":1,"tweetType":1,"viewCount":118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328874739536088,"gmtCreate":1721316901969,"gmtModify":1721316905428,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328874739536088","repostId":"2452177348","repostType":2,"repost":{"id":"2452177348","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1721293372,"share":"https://ttm.financial/m/news/2452177348?lang=&edition=fundamental","pubTime":"2024-07-18 17:02","market":"us","language":"en","title":"BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch","url":"https://stock-news.laohu8.com/highlight/detail?id=2452177348","media":"Reuters","summary":"(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)   By Aimee Donnellan      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more t","content":"<html><body><p>(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)</p><p>   By Aimee Donnellan</p><p>      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.</p><p>   Full view will be published shortly.</p><p>   Follow @aimeedonnellan on X</p><p>   CONTEXT NEWS</p><p>   Roche said on July 17 that a second drug candidate from its purchase of Carmot <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs. Novo Nordisk’s shares fell nearly 4% on the news.</p><p>   Pfizer said on July 11 that it plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year.</p><p>   The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections.</p><p> (Editing by Neil Unmack and Oliver Taslic)</p><p>((For previous columns by the author, Reuters customers can click on    Aimee.Donnellan@thomsonreuters.com))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-07-18 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)</p><p>   By Aimee Donnellan</p><p>      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.</p><p>   Full view will be published shortly.</p><p>   Follow @aimeedonnellan on X</p><p>   CONTEXT NEWS</p><p>   Roche said on July 17 that a second drug candidate from its purchase of Carmot <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs. Novo Nordisk’s shares fell nearly 4% on the news.</p><p>   Pfizer said on July 11 that it plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year.</p><p>   The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections.</p><p> (Editing by Neil Unmack and Oliver Taslic)</p><p>((For previous columns by the author, Reuters customers can click on    Aimee.Donnellan@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","BK4592":"伊斯兰概念","BK4532":"文艺复兴科技持仓","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","NVO":"诺和诺德","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","PFE":"辉瑞","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0109391861.USD":"富兰克林美国机遇基金A Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4581":"高盛持仓","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0058720904.USD":"联博国际健康护理基金A","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC"},"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2452177348","content_text":"(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)   By Aimee Donnellan      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.   Full view will be published shortly.   Follow @aimeedonnellan on X   CONTEXT NEWS   Roche said on July 17 that a second drug candidate from its purchase of Carmot Therapeutics yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs. Novo Nordisk’s shares fell nearly 4% on the news.   Pfizer said on July 11 that it plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year.   The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections. (Editing by Neil Unmack and Oliver Taslic)((For previous columns by the author, Reuters customers can click on    Aimee.Donnellan@thomsonreuters.com))","news_type":1},"isVote":1,"tweetType":1,"viewCount":111,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":271385007149168,"gmtCreate":1707293886836,"gmtModify":1707293891450,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"Anyone has the full article","listText":"Anyone has the full article","text":"Anyone has the full article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/271385007149168","repostId":"2409913541","repostType":2,"isVote":1,"tweetType":1,"viewCount":703,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9031765144,"gmtCreate":1646672052021,"gmtModify":1676534149273,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GRAB\">$Grab Holdings(GRAB)$</a>if i had bought this during ipo, i might be working for them slogging for that extra income to fill the gaps","listText":"<a href=\"https://ttm.financial/S/GRAB\">$Grab Holdings(GRAB)$</a>if i had bought this during ipo, i might be working for them slogging for that extra income to fill the gaps","text":"$Grab Holdings(GRAB)$if i had bought this during ipo, i might be working for them slogging for that extra income to fill the gaps","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9031765144","isVote":1,"tweetType":1,"viewCount":1131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9031765144,"gmtCreate":1646672052021,"gmtModify":1676534149273,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/GRAB\">$Grab Holdings(GRAB)$</a>if i had bought this during ipo, i might be working for them slogging for that extra income to fill the gaps","listText":"<a href=\"https://ttm.financial/S/GRAB\">$Grab Holdings(GRAB)$</a>if i had bought this during ipo, i might be working for them slogging for that extra income to fill the gaps","text":"$Grab Holdings(GRAB)$if i had bought this during ipo, i might be working for them slogging for that extra income to fill the gaps","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9031765144","isVote":1,"tweetType":1,"viewCount":1131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":340162317475968,"gmtCreate":1724051661746,"gmtModify":1724051665710,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/SEJ.SI\">$NoonTalk Media(SEJ.SI)$</a> Hitting 0 soon","listText":"<a href=\"https://ttm.financial/S/SEJ.SI\">$NoonTalk Media(SEJ.SI)$</a> Hitting 0 soon","text":"$NoonTalk Media(SEJ.SI)$ Hitting 0 soon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/340162317475968","isVote":1,"tweetType":1,"viewCount":119,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":332647088873720,"gmtCreate":1722220519167,"gmtModify":1722220523230,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"If getting suppliers locally is going to cut down on all the logistic costs, but still cost us more to buy them. Then no thanks.","listText":"If getting suppliers locally is going to cut down on all the logistic costs, but still cost us more to buy them. Then no thanks.","text":"If getting suppliers locally is going to cut down on all the logistic costs, but still cost us more to buy them. Then no thanks.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/332647088873720","repostId":"1162539099","repostType":2,"isVote":1,"tweetType":1,"viewCount":118,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":328874739536088,"gmtCreate":1721316901969,"gmtModify":1721316905428,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"Share your opinion about this news…","listText":"Share your opinion about this news…","text":"Share your opinion about this news…","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/328874739536088","repostId":"2452177348","repostType":2,"repost":{"id":"2452177348","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1721293372,"share":"https://ttm.financial/m/news/2452177348?lang=&edition=fundamental","pubTime":"2024-07-18 17:02","market":"us","language":"en","title":"BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch","url":"https://stock-news.laohu8.com/highlight/detail?id=2452177348","media":"Reuters","summary":"(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)   By Aimee Donnellan      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more t","content":"<html><body><p>(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)</p><p>   By Aimee Donnellan</p><p>      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.</p><p>   Full view will be published shortly.</p><p>   Follow @aimeedonnellan on X</p><p>   CONTEXT NEWS</p><p>   Roche said on July 17 that a second drug candidate from its purchase of Carmot <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs. Novo Nordisk’s shares fell nearly 4% on the news.</p><p>   Pfizer said on July 11 that it plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year.</p><p>   The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections.</p><p> (Editing by Neil Unmack and Oliver Taslic)</p><p>((For previous columns by the author, Reuters customers can click on    Aimee.Donnellan@thomsonreuters.com))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBREAKINGVIEWS-Novo Nordisk obesity feast no longer a free lunch\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2024-07-18 17:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)</p><p>   By Aimee Donnellan</p><p>      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.</p><p>   Full view will be published shortly.</p><p>   Follow @aimeedonnellan on X</p><p>   CONTEXT NEWS</p><p>   Roche said on July 17 that a second drug candidate from its purchase of Carmot <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs. Novo Nordisk’s shares fell nearly 4% on the news.</p><p>   Pfizer said on July 11 that it plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year.</p><p>   The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections.</p><p> (Editing by Neil Unmack and Oliver Taslic)</p><p>((For previous columns by the author, Reuters customers can click on    Aimee.Donnellan@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","BK4592":"伊斯兰概念","BK4532":"文艺复兴科技持仓","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4534":"瑞士信贷持仓","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","NVO":"诺和诺德","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","PFE":"辉瑞","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0109391861.USD":"富兰克林美国机遇基金A Acc","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4581":"高盛持仓","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0058720904.USD":"联博国际健康护理基金A","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC"},"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2452177348","content_text":"(The author is a Reuters Breakingviews columnist.  The opinions expressed are her own.)   By Aimee Donnellan      LONDON, July 18 (Reuters Breakingviews) - The $603 bln drug group’s shares have more than trebled since 2021 on the back of booming sales of weight-loss treatment Wegovy. To justify that, it will need to keep coming up with new, even better products, and fend off rivals like Pfizer. Neither looks certain.   Full view will be published shortly.   Follow @aimeedonnellan on X   CONTEXT NEWS   Roche said on July 17 that a second drug candidate from its purchase of Carmot Therapeutics yielded positive results in an early-stage trial, as the Swiss drugmaker asserted itself as a late contender in the race to develop obesity drugs. Novo Nordisk’s shares fell nearly 4% on the news.   Pfizer said on July 11 that it plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year.   The new drug is part of the second generation of weight-loss pills under development by companies including Eli Lilly and Novo Nordisk that will offer patients a more convenient alternative to injections. (Editing by Neil Unmack and Oliver Taslic)((For previous columns by the author, Reuters customers can click on    Aimee.Donnellan@thomsonreuters.com))","news_type":1},"isVote":1,"tweetType":1,"viewCount":111,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":271385007149168,"gmtCreate":1707293886836,"gmtModify":1707293891450,"author":{"id":"3583414482292207","authorId":"3583414482292207","name":"Woodbranch","avatar":"https://static.tigerbbs.com/60d7c475430bda5d8c7733c97fb4b6ac","crmLevel":5,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3583414482292207","idStr":"3583414482292207"},"themes":[],"htmlText":"Anyone has the full article","listText":"Anyone has the full article","text":"Anyone has the full article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/271385007149168","repostId":"2409913541","repostType":2,"repost":{"id":"2409913541","pubTimestamp":1707080410,"share":"https://ttm.financial/m/news/2409913541?lang=&edition=fundamental","pubTime":"2024-02-05 05:00","market":"us","language":"en","title":"Seatrium’s profit warning has a silver lining","url":"https://stock-news.laohu8.com/highlight/detail?id=2409913541","media":"businesstimes","summary":"PROFIT warnings are never good news for investors. Yet, there is a positive aspect to Seatrium’s announcement last week that it will report a significantly higher loss for 2023 than the previous year.","content":"<div>\n<p>PROFIT warnings are never good news for investors. Yet, there is a positive aspect to Seatrium’s announcement last week that it will report a significantly higher loss for 2023 than the previous year.</p>\n\n<a href=\"https://www.businesstimes.com.sg/opinion-features/seatriums-profit-warning-has-silver-lining\">Web Link</a>\n\n</div>\n","source":"bustime_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Seatrium’s profit warning has a silver lining</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSeatrium’s profit warning has a silver lining\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-02-05 05:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.businesstimes.com.sg/opinion-features/seatriums-profit-warning-has-silver-lining><strong>businesstimes</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>PROFIT warnings are never good news for investors. Yet, there is a positive aspect to Seatrium’s announcement last week that it will report a significantly higher loss for 2023 than the previous year.</p>\n\n<a href=\"https://www.businesstimes.com.sg/opinion-features/seatriums-profit-warning-has-silver-lining\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SGXZ58947870.SGD":"LIONGLOBAL SINGAPORE DIVIDEND EQUITY (SGDHDG) INC","SG9999013460.SGD":"LionGlobal Singapore Dividend Equity Fund SGD","SG9999002406.SGD":"利安新加坡信托基金","LU0532188223.SGD":"JPMorgan Funds - ASEAN Equity A (acc) SGD","SG9999013478.USD":"利安新加坡股息基金","SG9999013486.USD":"LIONGLOBAL SINGAPORE DIVIDEND EQUITY (USD) INC A","SG9999002620.SGD":"LionGlobal South East Asia SGD","BK6065":"建筑机械与重型卡车","BK6504":"工业制品概念","SG9999003826.SGD":"日兴资管新加坡股息基金 SGD","SG9999014492.USD":"NIKKO AM ASEAN EQUITY \"A\" (USD) ACC","SG9999002604.SGD":"LionGlobal Singapore/Malaysia SGD","SG9999004360.SGD":"Nikko AM Shenton Thrift Fund SGD","SG9999014484.SGD":"Nikko AM ASEAN Equity Fund A SGD","IE0034224299.USD":"PINEBRIDGE ASIA EX JAPAN EQUITY \"A\" (USD) ACC","SG9999002414.USD":"LIONGLOBAL SINGAPORE TRUST (USD) ACC"},"source_url":"https://www.businesstimes.com.sg/opinion-features/seatriums-profit-warning-has-silver-lining","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2409913541","content_text":"PROFIT warnings are never good news for investors. Yet, there is a positive aspect to Seatrium’s announcement last week that it will report a significantly higher loss for 2023 than the previous year.","news_type":1},"isVote":1,"tweetType":1,"viewCount":703,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}